신경보철 시장 : 시장 규모, 점유율, 동향 분석 보고서 - 유형별, 기술별, 용도별, 지역별, 부문별 예측(2025-2033년)

Neuroprosthetics Market Size, Share & Trends Analysis Report By Type, By Technology, By Application, By Region, And Segment Forecasts, 2025 - 2033

US $ 5,950 ￦ 8,819,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950 ￦ 10,301,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950 ￦ 13,265,000

Printable PDF & Excel (Enterprise License)

PDF & Excel 보고서를 동일 기업(자회사 포함)의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다. 인쇄물의 이용 범위는 파일의 이용 범위와 동일합니다.

한글목차

신경보철 시장 요약

세계의 신경보철 시장 규모는 2024년에 146억 2,000만 달러로 평가되었고, 2033년까지 470억 달러에 이를 것으로 예측됩니다.

2025-2033년 연평균 복합 성장률(CAGR) 13.69%로 성장할 전망입니다. 이 시장은 신경질환, 심장질환, 신장질환의 유병률 증가 및 의료 기술의 지속적인 진보에 의해 견인되고 있습니다.

또한 연구 활동 확대와 업계 성장에 대한 주력 강화가 향후 수년간 시장을 지원할 것으로 예측됩니다. 파킨슨병, 간질, 알츠하이머병, 우울증 등 신경질환의 부담이 현저하게 증가하고 있으며, 이는 신경보철 장치 수요를 촉진할 것으로 전망됩니다. 2024년 2월에 발표된 WHO 데이터에 따르면 세계 약 5,000만 명이 간질을 앓고 있습니다. 게다가, 신경질환의 부담은 다양한 인구통계군에서 여전히 크고, 신경보철 장치에 대한 수요 증가에 기여하고 있습니다. CDC에 따르면 2021-2022년 18세 이상의 미국 성인 약 290만 명이 활동성 간질을 가지고 있다고 보고되었습니다.

또한, 청각계, 안과계, 심장계, 신장계에 영향을 미치는 생리적 장애의 유병률 증가가 시장 성장을 견인할 것으로 예측됩니다. 2025년 2월에 발표된 WHO 데이터에 따르면, 2050년까지 약 25억 명이 어떠한 정도의 청력 상실을 경험하고, 7억 명 이상이 청각 재활을 필요로 할 수 있습니다.

현재 세계 인구의 5% 이상에 해당하는 4억 3,000만 명 이상(그 중 3,400만 명이 아이)이 난청 재활을 필요로 하고 있습니다. 이 수는 2050년까지 7억 명(약 10명에 1명)을 넘을 것으로 예측되고 있습니다. 청각장애인의 약 80%는 중저소득국에 거주하고 있으며, 그 유병률은 연령과 함께 상승하여 60세 이상의 성인의 25% 이상에 영향을 미치고 있습니다. 이 세계의 청각 장애 증가 추세는 예측 기간 동안 인공 내이 수요를 촉진하고 시장 확대를 지원할 것으로 예측됩니다.

목차

제1장 조사 방법 및 범위

제2장 주요 요약

제3장 신경보철의 변수, 동향 및 범위

• 시장 계보의 전망
  • 상위 시장 전망
  • 관련 및 부수 시장 전망
• 시장 역학
• 신경보철 분석 도구
  • 업계 분석 : Porter's Five Forces
  • PESTEL 분석

제4장 신경보철 시장 : 유형별(2021-2033년)

• 정의 및 범위
• 시장 점유율 분석 : 유형별(2024년, 2033년)
• 세계의 신경보철 시장 : 유형별(2021-2033년)
• 시장 규모, 예측 및 동향 분석(2021-2033년)

제5장 신경보철 시장 : 용도별(2021-2033년)

• 정의 및 범위
• 시장 점유율 분석 : 용도별(2024년, 2033년)
• 세계의 신경보철 시장 : 용도별(2021-2033년)
• 시장 규모, 예측 및 동향 분석(2021-2033년)

제6장 신경보철 시장 : 기술별(2021-2033년)

• 정의 및 범위
• 시장 점유율 분석 : 기술별(2024년, 2033년)
• 세계의 신경보철 시장 : 기술별(2021-2033년)
• 시장 규모, 예측 및 동향 분석(2021-2033년)

제7장 신경보철 시장 : 지역별 추정 및 동향 분석

• 지역별 대시보드
• 시장 규모, 예측 및 동향 분석(2021-2033년)
• 북미
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 영국
  • 독일
  • 프랑스
  • 이탈리아
  • 스페인
  • 노르웨이
  • 스웨덴
  • 덴마크
• 아시아태평양
  • 일본
  • 중국
  • 인도
  • 호주
  • 한국
  • 태국
• 라틴아메리카
  • 브라질
  • 아르헨티나
• 중동 및 아프리카
  • 남아프리카
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 쿠웨이트

제8장 경쟁 구도

• 주요 시장 진출기업별 최근의 동향 및 영향 분석
• 기업 및 경쟁의 분류
  • 이노베이터
• 벤더 상황
  • 주요 유통업체 및 채널 파트너 목록
  • 주요 고객
  • 세계 주요 기업의 시장 점유율 분석(2024년)
  • Medtronic
  • LivaNova PLC
  • Cochlear Ltd.
  • Abbott
  • Boston Scientific Corporation
  • Nevro Corp
  • Sonova
  • Science Corporation
  • Advanced Bionics AG
  • MED-EL Medical Electronics
  • ZHEJIANG NUROTRON BIOTECHNOLOGY CO., LTD.
• 히트맵 분석 및 기업 시장 포지셔닝 분석
• 추정 기업 점유율 분석(2024년)
• 기타 주요 시장 기업 일람

AJY

영문 목차

영문목차

Neuroprosthetics Market Summary

The global neuroprosthetics market size was estimated at USD 14.62 billion in 2024 and is projected to reach USD 47.0 billion by 2033, growing at a CAGR of 13.69% from 2025 to 2033. The market is driven by the increasing prevalence of neurological, cardiac, and kidney disorders, as well as ongoing advancements in medical technology.

In addition, expanded research efforts and a greater focus on industry growth are anticipated to support the market in the coming years. The burden of neurological disorders such as Parkinson's disease, epilepsy, Alzheimer's disease, and depression is increasing significantly, which is anticipated to propel the demand for neuroprosthetic devices. According to the WHO data published in February 2024, approximately 50 million people worldwide are living with epilepsy. Furthermore, the burden of neurological disorders remains significant across various demographic groups, contributing to the rising demand for neuroprosthetic devices. According to the CDC, approximately 2.9 million U.S. adults aged 18 and older reported having active epilepsy during 2021 and 2022.

Furthermore, the increasing prevalence of physiological disorders, particularly those affecting the auditory, ophthalmic, cardiac, and renal systems, is expected to drive market growth. According to WHO data published in February 2025, around 2.5 billion people may experience some extent of hearing loss by 2050, with over 700 million requiring hearing rehabilitation.

Currently, over 430 million individuals, representing more than 5% of the global population, including 34 million children, require rehabilitation for hearing loss. This number is projected to exceed 700 million, or about 1 in 10 people, by 2050. Around 80% of those with hearing loss live in low- and middle-income countries, and prevalence rises with age, affecting over 25% of adults above 60. This increasing global burden of auditory disorders is expected to drive demand for cochlear implants and support market expansion during the forecast period.

Global Neuroprosthetics Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global neuroprosthetics market report based on type, technology, application, and region:

• Type Outlook (Revenue, USD Million, 2021 - 2033)
• Motor Prosthetics
• Cochlear Implants
• Cognitive Prosthetics
• Retinal Implants
• Technology Outlook (Revenue, USD Million, 2021 - 2033)
• Deep Brain Stimulation (DBS)
• Vagus Nerve Stimulation (VNS)
• Spinal Cord Stimulation (SCS)
• Sacral Nerve Stimulation (SNS)
• Application Outlook (Revenue, USD Million, 2021 - 2033)
• Motor Neuron Disorders
  • Parkinson's Disease
  • Epilepsy
• Physiological Disorders
  • Auditory Disorders
  • Opthalmic Disorders
  • Cardiac Disorders
  • Kidney Disorders
• Cognitive Disorders
  • Alzheimer's Disease
  • Severe Depression
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Norway
  • Denmark
  • Sweden
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East and Africa (MEA)
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Content

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Segment Definitions
  • 1.2.1. Type
  • 1.2.2. Applications
  • 1.2.3. Technology
  • 1.2.4. Regional Scope
  • 1.2.5. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Regional outlook
• 2.4. Competitive Insights

Chapter 3. Neuroprosthetics Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Increasing Prevalence of Target Diseases
    • 3.2.1.2. Technological Advancements In Neuroprosthetics
    • 3.2.1.3. Rising Number of Awareness Initiatives
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. Product Recalls
  • 3.2.3. Market Opportunity Analysis
    • 3.2.3.1. Growing Number of Clinical Trials
    • 3.2.3.2. Launches Of Novel Products
    • 3.2.3.3. Increasing Research & Development Activities
  • 3.2.4. Market Challenge Analysis
    • 3.2.4.1. Shortage of Skilled Professionals
    • 3.2.4.2. Potential Complications & Risks Associated with Neuroprosthetics
• 3.3. Neuroprosthetics Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Bargaining power of suppliers
    • 3.3.1.2. Bargaining power of buyers
    • 3.3.1.3. Threat of substitutes
    • 3.3.1.4. Threat of new entrants
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Economic landscape
    • 3.3.2.3. Social landscape
    • 3.3.2.4. Technological landscape
    • 3.3.2.5. Environmental landscape
    • 3.3.2.6. Legal landscape

Chapter 4. Neuroprosthetics Market: Segment Analysis, By Type, 2021 - 2033 (USD Million)

• 4.1. Definition and Scope
• 4.2. Type Market Share Analysis, 2024 & 2033
• 4.3. Global Neuroprosthetics Market, by Type, 2021 to 2033
• 4.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033
  • 4.4.1. Motor Prosthetics
    • 4.4.1.1. Motor prosthetics devices market, 2021 - 2033 (USD Million)
  • 4.4.2. Cochlear Implants
    • 4.4.2.1. Cochlear implants market, 2021 - 2033 (USD Million)
  • 4.4.3. Cognitive Prosthetics
    • 4.4.3.1. Cognitive prosthetics market, 2021 - 2033 (USD Million)
  • 4.4.4. Retinal Implants
    • 4.4.4.1. Retinal implants market, 2021 - 2033 (USD Million)

Chapter 5. Neuroprosthetics Market: Segment Analysis, By Applications, 2021 - 2033 (USD Million)

• 5.1. Definition and Scope
• 5.2. Applications Market Share Analysis, 2024 & 2033
• 5.3. Global Neuroprosthetics Market, by Applications, 2021 to 2033
• 5.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033
  • 5.4.1. Motor Neuron Disorders
    • 5.4.1.1. Motor neuron disorders market, 2021 - 2033 (USD Million)
    • 5.4.1.2. Parkinson's Disease
      • 5.4.1.2.1. Parkinson's disease market, 2021 - 2033 (USD Million)
    • 5.4.1.3. Epilepsy
      • 5.4.1.3.1. Epilepsy market, 2021 - 2033 (USD Million)
  • 5.4.2. Physiological Disorders
    • 5.4.2.1. Physiological disorders market, 2021 - 2033 (USD Million)
    • 5.4.2.2. Auditory Disorders
      • 5.4.2.2.1. Auditory disorders market, 2021 - 2033 (USD Million)
    • 5.4.2.3. Ophthalmic Disorders
      • 5.4.2.3.1. Ophthalmic disorders market, 2021 - 2033 (USD Million)
    • 5.4.2.4. Cardiac Disorders
      • 5.4.2.4.1. Cardiac disorders market, 2021 - 2033 (USD Million)
    • 5.4.2.5. Kidney Disorders
      • 5.4.2.5.1. Kidney disorders market, 2021 - 2033 (USD Million)
  • 5.4.3. Cognitive Disorders
    • 5.4.3.1. Cognitive disorders market, 2021 - 2033 (USD Million)
    • 5.4.3.2. Alzheimer's Disease
      • 5.4.3.2.1. Alzheimer's disease market, 2021 - 2033 (USD Million)
    • 5.4.3.3. Severe Depression
      • 5.4.3.3.1. Severe depression market, 2021 - 2033 (USD Million)

Chapter 6. Neuroprosthetics Market: Segment Analysis, By Technology, 2021 - 2033 (USD Million)

• 6.1. Definition and Scope
• 6.2. Technology Market Share Analysis, 2024 & 2033
• 6.3. Global Neuroprosthetics Market, by Technology, 2021 to 2033
• 6.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033
  • 6.4.1. Deep Brain Stimulation
    • 6.4.1.1. Deep brain stimulation market, 2021 - 2033 (USD Million)
  • 6.4.2. Vagus Nerve Stimulation
    • 6.4.2.1. Vagus nerve stimulation market, 2021 - 2033 (USD Million)
  • 6.4.3. Spinal Cord Stimulation
    • 6.4.3.1. Spinal cord stimulation market, 2021 - 2033 (USD Million)
  • 6.4.4. Sacral Nerve Stimulation
    • 6.4.4.1. Sacral nerve stimulation market, 2021 - 2033 (USD Million)

Chapter 7. Neuroprosthetics Market: Regional Estimates & Trend Analysis

• 7.1. Regional Dashboard
• 7.2. Market Size, & Forecasts Trend Analysis, 2021 to 2033:
• 7.3. North America
  • 7.3.1. U.S.
    • 7.3.1.1. Key country dynamics
    • 7.3.1.2. Regulatory framework/ reimbursement structure
    • 7.3.1.3. Competitive scenario
    • 7.3.1.4. U.S. market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.3.2. Canada
    • 7.3.2.1. Key country dynamics
    • 7.3.2.2. Regulatory framework/ reimbursement structure
    • 7.3.2.3. Competitive scenario
    • 7.3.2.4. Canada market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.3.3. Mexico
    • 7.3.3.1. Key country dynamics
    • 7.3.3.2. Regulatory framework/ reimbursement structure
    • 7.3.3.3. Competitive scenario
    • 7.3.3.4. Mexico market estimates and forecasts 2021 to 2033 (USD Million)
• 7.4. Europe
  • 7.4.1. UK
    • 7.4.1.1. Key country dynamics
    • 7.4.1.2. Regulatory framework/ reimbursement structure
    • 7.4.1.3. Competitive scenario
    • 7.4.1.4. UK market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.4.2. Germany
    • 7.4.2.1. Key country dynamics
    • 7.4.2.2. Regulatory framework/ reimbursement structure
    • 7.4.2.3. Competitive scenario
    • 7.4.2.4. Germany market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.4.3. France
    • 7.4.3.1. Key country dynamics
    • 7.4.3.2. Regulatory framework/ reimbursement structure
    • 7.4.3.3. Competitive scenario
    • 7.4.3.4. France market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.4.4. Italy
    • 7.4.4.1. Key country dynamics
    • 7.4.4.2. Regulatory framework/ reimbursement structure
    • 7.4.4.3. Competitive scenario
    • 7.4.4.4. Italy market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.4.5. Spain
    • 7.4.5.1. Key country dynamics
    • 7.4.5.2. Regulatory framework/ reimbursement structure
    • 7.4.5.3. Competitive scenario
    • 7.4.5.4. Spain market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.4.6. Norway
    • 7.4.6.1. Key country dynamics
    • 7.4.6.2. Regulatory framework/ reimbursement structure
    • 7.4.6.3. Competitive scenario
    • 7.4.6.4. Norway market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.4.7. Sweden
    • 7.4.7.1. Key country dynamics
    • 7.4.7.2. Regulatory framework/ reimbursement structure
    • 7.4.7.3. Competitive scenario
    • 7.4.7.4. Sweden market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.4.8. Denmark
    • 7.4.8.1. Key country dynamics
    • 7.4.8.2. Regulatory framework/ reimbursement structure
    • 7.4.8.3. Competitive scenario
    • 7.4.8.4. Denmark market estimates and forecasts 2021 to 2033 (USD Million)
• 7.5. Asia Pacific
  • 7.5.1. Japan
    • 7.5.1.1. Key country dynamics
    • 7.5.1.2. Regulatory framework/ reimbursement structure
    • 7.5.1.3. Competitive scenario
    • 7.5.1.4. Japan market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.5.2. China
    • 7.5.2.1. Key country dynamics
    • 7.5.2.2. Regulatory framework/ reimbursement structure
    • 7.5.2.3. Competitive scenario
    • 7.5.2.4. China market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.5.3. India
    • 7.5.3.1. Key country dynamics
    • 7.5.3.2. Regulatory framework/ reimbursement structure
    • 7.5.3.3. Competitive scenario
    • 7.5.3.4. India market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.5.4. Australia
    • 7.5.4.1. Key country dynamics
    • 7.5.4.2. Regulatory framework/ reimbursement structure
    • 7.5.4.3. Competitive scenario
    • 7.5.4.4. Australia market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.5.5. South Korea
    • 7.5.5.1. Key country dynamics
    • 7.5.5.2. Regulatory framework/ reimbursement structure
    • 7.5.5.3. Competitive scenario
    • 7.5.5.4. South Korea market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.5.6. Thailand
    • 7.5.6.1. Key country dynamics
    • 7.5.6.2. Regulatory framework/ reimbursement structure
    • 7.5.6.3. Competitive scenario
    • 7.5.6.4. Thailand market estimates and forecasts 2021 to 2033 (USD Million)
• 7.6. Latin America
  • 7.6.1. Brazil
    • 7.6.1.1. Key country dynamics
    • 7.6.1.2. Regulatory framework/ reimbursement structure
    • 7.6.1.3. Competitive scenario
    • 7.6.1.4. Brazil market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.6.2. Argentina
    • 7.6.2.1. Key country dynamics
    • 7.6.2.2. Regulatory framework/ reimbursement structure
    • 7.6.2.3. Competitive scenario
    • 7.6.2.4. Argentina market estimates and forecasts 2021 to 2033 (USD Million)
• 7.7. MEA
  • 7.7.1. South Africa
    • 7.7.1.1. Key country dynamics
    • 7.7.1.2. Regulatory framework/ reimbursement structure
    • 7.7.1.3. Competitive scenario
    • 7.7.1.4. South Africa market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.7.2. Saudi Arabia
    • 7.7.2.1. Key country dynamics
    • 7.7.2.2. Regulatory framework/ reimbursement structure
    • 7.7.2.3. Competitive scenario
    • 7.7.2.4. Saudi Arabia market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.7.3. UAE
    • 7.7.3.1. Key country dynamics
    • 7.7.3.2. Regulatory framework/ reimbursement structure
    • 7.7.3.3. Competitive scenario
    • 7.7.3.4. UAE market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.7.4. Kuwait
    • 7.7.4.1. Key country dynamics
    • 7.7.4.2. Regulatory framework/ reimbursement structure
    • 7.7.4.3. Competitive scenario
    • 7.7.4.4. Kuwait market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Recent Developments & Impact Analysis, By Key Market Participants
• 8.2. Company/Competition Categorization
  • 8.2.1. Innovators
• 8.3. Vendor Landscape
  • 8.3.1. List of key distributors and channel partners
  • 8.3.2. Key customers
  • 8.3.3. Global Key company market share analysis, 2024
  • 8.3.4. Medtronic
    • 8.3.4.1. Company overview
    • 8.3.4.2. Financial performance
    • 8.3.4.3. Product benchmarking
    • 8.3.4.4. Strategic initiatives
  • 8.3.5. LivaNova PLC
    • 8.3.5.1. Company overview
    • 8.3.5.2. Financial performance
    • 8.3.5.3. Product benchmarking
    • 8.3.5.4. Strategic initiatives
  • 8.3.6. Cochlear Ltd.
    • 8.3.6.1. Company overview
    • 8.3.6.2. Financial performance
    • 8.3.6.3. Product benchmarking
    • 8.3.6.4. Strategic initiatives
  • 8.3.7. Abbott
    • 8.3.7.1. Company overview
    • 8.3.7.2. Financial performance
    • 8.3.7.3. Product benchmarking
    • 8.3.7.4. Strategic initiatives
  • 8.3.8. Boston Scientific Corporation
    • 8.3.8.1. Company overview
    • 8.3.8.2. Financial performance
    • 8.3.8.3. Product benchmarking
    • 8.3.8.4. Strategic initiatives
  • 8.3.9. Nevro Corp
    • 8.3.9.1. Company overview
    • 8.3.9.2. Financial performance
    • 8.3.9.3. Product benchmarking
    • 8.3.9.4. Strategic initiatives
  • 8.3.10. Sonova
    • 8.3.10.1. Company overview
    • 8.3.10.2. Financial performance
    • 8.3.10.3. Product benchmarking
    • 8.3.10.4. Strategic initiatives
  • 8.3.11. Science Corporation
    • 8.3.11.1. Company overview
    • 8.3.11.2. Financial performance
    • 8.3.11.3. Product benchmarking
    • 8.3.11.4. Strategic initiatives
  • 8.3.12. Advanced Bionics AG
    • 8.3.12.1. Company overview
    • 8.3.12.2. Financial performance
    • 8.3.12.3. Product benchmarking
    • 8.3.12.4. Strategic initiatives
  • 8.3.13. MED-EL Medical Electronics
    • 8.3.13.1. Company overview
    • 8.3.13.2. Financial performance
    • 8.3.13.3. Product benchmarking
    • 8.3.13.4. Strategic initiatives
  • 8.3.14. ZHEJIANG NUROTRON BIOTECHNOLOGY CO., LTD.
    • 8.3.14.1. Company overview
    • 8.3.14.2. Financial performance
    • 8.3.14.3. Product benchmarking
    • 8.3.14.4. Strategic initiatives
• 8.4. Heat Map Analysis/ Company Market Position Analysis
• 8.5. Estimated Company Market Share Analysis, 2024
• 8.6. List of Other Key Market Players

관련자료